NDA 021938/S-37

SUPPLEMENT APPROVAL

C.P. Pharmaceuticals International C.V.
Attention: Nathaniel Asamere
Senior Manager
445 Eastern Point Rd.
Groton, CT 06340

Dear Mr. Asamere:

Please refer to your supplemental new drug application dated and received July 17, 2019, and your amendments dated December 20, 2019, January 8, 16, and 24, 2020, February 7, and 28, 2020, March 24, 2020, May 19, 2020, June 29, 2020, July 27, 2020, and August 12, 2020, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Sutent (sunitinib malate) capsules.

This Prior Approval supplemental new drug application provides for updates to the following:

- Updates to the WARNINGS AND PRECAUTIONS subsection (5.14), retitled Impaired Wound Healing, to provide recommendations for withholding SUTENT prior to elective surgery and for resumption of SUTENT after surgery;
- Addition of Reversible Posterior Leukoencephalopathy Syndrome (RPLS) to WARNINGS AND PRECAUTIONS subsection (5.10), information regarding RPLS previously in subsection 6.1 was incorporated into subsection 5.10;
- Updates to the WARNINGS AND PRECAUTIONS subsection (5.13), Osteonecrosis of the Jaw (ONJ), to provide recommendations for withholding SUTENT prior to scheduled dental surgery or invasive dental procedures and dose modifications for SUTENT after development of ONJ;
- Edits to the DOSAGE AND ADMINISTRATION subsections (2.1, 2.3, and 2.4) to clarify the recommended duration of treatment for GIST, advanced RCC, and pNET and the dosage modification for adverse reactions;
- Revisions to the PATIENT COUNSELING INFORMATION (17) and to the Medication Guide for consistency with the new and updated information in subsections 5.10, 5.13, and 5.14;
- Revisions to the HIGHLIGHTS OF PRESCRIBING INFORMATION to add Reversible Posterior Leukoencephalopathy Syndrome (RPLS), and revise Osteonecrosis of the Jaw and Impaired Wound Healing for consistency with revisions made to subsections 5.13 and 5.14, respectively;

- Updates to the table of contents consistent with revisions to the Full Prescribing Information;
- Updates to the carton and container labels to provide quantitative information consistent with information added to the U.S. package insert; and
- Editorial and formatting changes throughout the U.S. package insert for brevity and consistency with current labeling practices.

APPROVAL & LABELING

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.[1] Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Patient Package Insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.[2]

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this new drug application (NDA), including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well

[1] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
[2] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the submitted on February 28, 2020 carton and container labeling, except with the revisions listed above, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission "**Final Printed Carton and Container Labeling for approved NDA 021938/S-37**." Approval of this submission by FDA is not required before the labeling is used.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

PROMOTIONAL MATERIALS

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above, by fax to 301-847-8444, or electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions you may contact Felicia Diggs, Safety Regulatory Project Manager, at (240) 402-4932 or via email at Felicia.diggs@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Meredith K. Chuk, M.D.
Associate Director for Safety
Office of Oncologic Diseases
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
  - Prescribing Information
  - Medication Guide

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

MEREDITH K CHUK
08/14/2020 05:55:53 PM